Kistler-Tiffany Companies’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Kistler-Tiffany Companies’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$63.3K	Hold	1,000	–	–	0.01%	465
2023 Q1	$54.1K	Hold	1,000	–	–	0.01%	425
2022 Q4	$52.9K	Hold	1,000	–	–	0.01%	409
2022 Q3	$47K	Hold	1,000	–	–	0.01%	391
2022 Q2	$57K	Hold	1,000	–	–	0.01%	365
2022 Q1	$61K	Hold	1,000	–	–	0.01%	368
2021 Q4	$52K	Hold	1,000	–	–	0.01%	376
2021 Q3	$37K	Hold	1,000	–	–	0.01%	409
2021 Q2	$41K	Hold	1,000	–	–	0.01%	393
2021 Q1	$34K	Hold	1,000	–	–	0.01%	382
2020 Q4	$32K	Hold	1,000	–	–	0.01%	362
2020 Q3	$26K	Hold	1,000	–	–	0.01%	364
2020 Q2	$26K	Hold	1,000	–	–	0.01%	333
2020 Q1	$34K	Hold	1,000	–	–	0.01%	298
2019 Q4	$34K	Buy	+1,000	New	+$12K	0.01%	305

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kistler-Tiffany Companies's ITCI Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q2 2023 at 1,000 shares worth $63.3K. The position accounts for 0.01% of the portfolio, ranked #465.

Kistler-Tiffany Companies first reported a position in ITCI in Q4 2019 and has held it in 15 quarters since. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

Kistler-Tiffany Companies held 1,000 shares of Intra-Cellular Therapies Inc. worth $63.3K as of Q2 2023.
Kistler-Tiffany Companies left its Intra-Cellular Therapies Inc. share count unchanged in Q2 2023.
Intra-Cellular Therapies Inc. made up 0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #465 holding.
Kistler-Tiffany Companies first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and has held it in 15 quarters since.
288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.